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Abstract
Background: Impaired active digital extension is common after stroke, hindering functional rehabilitation, and predicting poor
recovery. The SaeboGlove assists digital extension and may improve outcome after stroke. We recently performed a single
group, open, pilot trial of the SaeboGlove early after stroke which demonstrated satisfactory safety, feasibility and acceptability.
An adequately powered randomised clinical trial is now needed to assess the clinical effectiveness of the SaeboGlove.
Methods: SUSHI is a pragmatic, multicentre, parallel-group, randomised controlled trial with blinded outcome assess-
ment, and embedded process and economic evaluations. Adults, 7–60 days post-stroke, with upper limb disability and
severe hand impairment, including reduced active digital extension, will be recruited from NHS inpatient stroke services
in Scotland. Participants will be randomised on a 1:1 basis to receive 6 weeks of self-directed, repetitive, functional-based
practice involving a SaeboGlove plus usual care, or usual care only. The primary outcome is upper limb function
measured by the Action Research Arm Test (ARAT) at 6 weeks. Secondary outcomes will be measured at 6 and 14
weeks. A process evaluation will be performed via interviews with ‘intervention’ participants, and their carers and
clinical therapists. A within-trial cost-effectiveness analysis will be performed. 110 participants are required to detect a
difference between groups of 9 in the ARATwith 90% power at a 5% significance level allowing for 11% attrition.
Discussion: SUSHI will determine if SaeboGlove self-directed, repetitive, functional-based practice improves upper
limb function after stroke, whether it is acceptable to stroke survivors and whether it is cost-effective.
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Background
Stroke is the third leading cause of disability world-
wide.1 Upper limb motor impairment contributes signif-
icantly to the burden experienced by stroke survivors. It
affects around 80% of people with stroke2 and approx-
imately 50% of them have no improvement in upper
limb function six months post-stroke.3 Long-term
upper limb impairment is associated with increased dis-
ability4 and reduced quality of life.5
Impaired active digital extension is the most
common upper limb motor impairment after stroke.6
It reduces hand opening essential for upper limb func-
tion7 and predicts poor upper limb recovery.8
Repetitive, functional-based rehabilitation and
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self-practice activities are advocated by national clini-
cal guidelines9,10 and systematic review evidence.11–13
However, lack of active digital extension can prevent
people accessing guideline-based activities, both in clin-
ical14,15 and research16 settings, and no evidence-based
interventions have been identified to improve this.3,13,17
This may account for the particularly poor upper limb
prognosis experienced after stroke.
The SaeboGlove is a CE marked mechanical hand
orthosis already used in some health services. It con-
sists of a glove, fixed using velcro inside a wrist splint
(Figure 1),18 and offers digital extensor assistance using
tensioner bands which span between hooks over weak
joints to enable hand opening.18 Consequently, it
improves access to repetitive, functional-based upper
limb rehabilitation and self-practice opportunities,19
regardless of extensor weakness severity. This might
promote engagement in recommended rehabilitation
activities and improve long-term recovery; addressing
key priorities in stroke care.
We recently completed a single-group pilot trial of
four weeks of SaeboGlove self-directed, repetitive,
functional-based practice in people with reduced
active digital extension early after stroke (n¼ 12,
mean (range) 27 (4–80) days post).19 The intervention
was found to be safe, feasible and acceptable. We used
the revised, standardised20 and validated21 version of
the original ARAT by Lyle22 (scale 0–57) which does
not specify time limits. As this test has been historically
described as a measure of upper limb function, a term
that aligns with upper limb activity capacity within The
International Classification of Functioning, Disability
and Health model, this manuscript will continue to use
this terminology. ARAT scores improved by a mean
(SD) of 18.8 (13.5) points.19 This improvement is
nearly double that observed in historical controls (10
(15) points)23 but the absence of a control group limits
interpretation.
In this protocol paper, we describe the SUSHI trial.
The primary objective of the SUSHI trial is to assess
the clinical effectiveness of SaeboGlove self-directed,
repetitive, functional-based practice plus usual care
when compared to usual care alone in people with
upper limb disability and severe hand impairment,
including reduced active digital extension after recent
stroke. We hypothesise that upper limb function
(ARAT) will be significantly greater in the intervention
group immediately post intervention.
Methods
Trial design
The SUSHI trial is a pragmatic, multicentre, parallel-
group, RCT comparing self-directed, repetitive,
functional-based practice with a SaeboGlove plus
usual care, to usual care alone. The trial includes
blinded outcome assessments with embedded process
and economic evaluation. Follow-up for primary and
secondary outcomes will occur at 6 and 14 weeks post
randomisation. A further follow-up will be performed
at 6 months to inform assessment of long-term benefits
and economic evaluation. Figure 2 provides an over-
view of the SUSHI trial. The study is presented accord-
ing to the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT)24 and a summary is
provided in Table 1.
Trial setting
Participants will be recruited within NHS Inpatient
Stroke Services in Scotland.
Trial status
The study is registered on ClinicalTrials.gov
(NCT04007315, 5 July 2019). Participant recruitment
started in November 2019 (protocol version 2.0, 15th
July 2019, current 3.0, 14th April 2020). Recruitment
was suspended in March 2020 due to Covid-19 after 16
participants were randomised. Enrolment began again
in July 2020 and is expected to close in July 2022.
Ethical/regulatory approval
The study sponsor is the NHS GG&C Health Board.
The study will be performed in line with the
Declaration of Helsinki. Ethical approval was granted
by the West of Scotland Research Ethics Committee
(REC) 1 in August 2019 (19/WS/0097). NHS Board
Figure 1. The SaeboGlove. The SaeboGlove consists of a glove
velcroed inside a wrist splint, and bands of different size that
offer variable extensor assistance. This assistance increases hand
opening when it is limited, improving access to recommended
rehabilitation activities.
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approvals were granted by NHS GG&C (GN19ST318)
and NHS Lanarkshire (L19046) in November 2019. At
the time of writing approval from other sites is awaited.
The Principal Investigator at each site will be notified
of protocol amendments. The SaeboGlove is CE
marked for use as a rehabilitation device so prior reg-
ulatory approval from the MHRA is not required.
Eligibility criteria
Participants aged 18 years or older with a new clinical
stroke diagnosis that occurred 7–60 days prior to enrol-
ment will be included in the study if they have upper
limb disability (ARAT 46) and severe hand impair-
ment (Fugl Meyer Upper Extremity scale (FMUE)
hand sub-section 7, and reduced active digital exten-
sion). The ARAT range was based on feasibility data
and the limited function in this group.25 A full list of
the inclusion and exclusion criteria are listed in Table 2.
Case ascertainment, consent and screening
Potential participants will be identified by clinical care
teams. Once identified, site personnel will provide a
patient information leaflet and discuss study require-
ments with potential participants. To check eligibility,
a screening assessment will then be performed
(Table 1). Eligibility will be re-confirmed at the baseline
assessment if it takes place >48 hours after initial
screening or if the assessor has any concerns over a
change in eligibility since it was initially checked
(Table 1).
Baseline assessments
The baseline assessment will be carried out by trained
site personnel, and will include assessing upper limb
impairment (FMUE), perceived habitual functional
upper limb use (Motor Activity Log (MAL)), degree
of disability or dependence (modified Rankin Scale
(mRS)), activities of daily living (Barthel Index (BI),
quality of life (Stroke Impact Scale (version 3.0, UK)
(SIS), EuroQuol (EQ-5D-5L), upper limb pain intensi-
ty (visual analogue scale (VAS)), NHS and social serv-
ices resource use pre-stroke and current upper limb
treatment (Table 1). Details on each measure are
given in the online Supplementary material.
Randomisation
A central online randomisation service will be used,
developed and maintained by the Robertson Centre
for Biostatistics, University of Glasgow. Participants
will be allocated, on a 1:1 basis, to receive 6 weeks of
SaeboGlove self-directed, repetitive, functional-based
practice plus usual NHS care or 6 weeks of usual
NHS care. A minimisation algorithm (with a small
random element) will be applied, designed to maintain
balanced allocations with respect to study site, time
since stroke (1 month, >1 month) and severity of
upper limb function (ARAT 0–10, 11–28, 29–46).
When randomised, only nominated unblinded site per-
sonnel will be emailed with group allocation details to
progress blinded tasks.
Figure 2. Overview of methods used for RCT, and process and economic evaluations.
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Interventions
Usual care. All participants will receive usual NHS care.
Usual care involves an evidence-based approach tai-
lored to each individual’s needs, and is based on
National Clinical Guidelines that recommend a mini-
mum of 45minutes of physiotherapy and occupational
therapy, five days per week.9,10 Therapy teams will be
asked to record the usual care they provide during the
intervention period on a study specific form (content,
dose (time/movement repetitions), achievement of rec-
ommended 45-minute duration).
Intervention group. First use of the SaeboGlove should
be within 48 hours of randomisation and must be
within one week of the baseline assessment.
Participants in the intervention group will be given a
SaeboGlove to use for 6 weeks. A therapist (physio-
therapist/occupational) from the study team, trained
in how to measure, fit and use the SaeboGlove will
train participants and any assisting carers (informal
or Health Care Worker) how to don/doff the glove
and establish an individualised self-directed, repetitive,
functional-based practice training programme involv-
ing grasping/releasing. A detailed description of the






screening) Intervention Outcome assessments
Pre week 0 Week 0 Weeks 1–6 Week 6 Week 14 Month 6





HandþWrist movement (Active, and passive
(contracturesþ spasticity)
X
Hand impairment (Hand sub-section of
Fugl Meyer upper extremity scale)
X *
Upper limb function (Action Research Arm Test) X * X* X
Screening check list X
Current upper limb treatment X
Upper limb impairment
(Fugl Meyer upper extremity scale)
X X X
Habitual functional use (Motor Activity Log) X X X X
Degree of disability (Modified Rankin Scale) X X X X
Activities of daily living (Barthel Index) X X X
Quality of life
(EQ-5D-5L) X X X X
(Stroke Impact Scale) X X X
Upper limb pain intensity (Visual analogy scale) X X X
NHS and social services resource use questionnaire X X X
Randomisation X
Adverse events X X X
SaeboGlove therapy plus usual care X (Intervention
group)





Usual care recorded X
Recommendations for Interventional Trials (SPIRIT): Schedule of enrolment, interventions, assessments and visits. EQ-5D-5L: EuroQol with 5
Dimensions and 5 Levels, UL: Upper limb.
*Hand sub-section and ARATonly repeated if baseline assessment occurs>48 hours after the screening assessment or if it occurred<48 hours ago and
assessor is concerned that eligibility may have changed. * represents the primary outcome. ** Optional 6weeks of SaeboGlove therapy offered after
14week outcome visit is completed.
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intervention used is shown using the Template for
Intervention Description and Replication (TIDieR)
Checklist26 provided in the Supplement. All therapists
will have observed at least one SaeboGlove therapy
session with a therapist with over 3 years’ experience
in its use. Therapists will encourage participants to
carry out their training programme daily and will pro-
vide a review session during 4 of the 6 weeks to assess
progress and re-define their individualised upper limb
treatment plan. Participants and their therapist will
agree shared intensity goals for their daily practice
(number of hand opening movements to aim to per-
form) at each review. If a participant is discharged
during the intervention period, they will travel back
to their local hospital to attend remaining review
appointments. If this is not possible then advice will
be provided by telephone.
Control group. Control participants will also receive a
review with a therapist (physiotherapist/occupational)
during 4 of the 6 weeks to assess progress and re-define
their usual care individualised upper limb treatment
plan and goals.
After the week 14 outcome assessment is completed,
usual care participants will be offered 6 weeks of
SaeboGlove self-directed, repetitive, functional-based
practice. This is to minimise attrition in the control
group. Data collected during this 6 week period will
not be a part of the formal efficacy analysis.
Hand and arm rehabilitation booklets. All participants will
be given a Hand and Arm rehabilitation exercise book-
let to encourage self-management by recording and
monitoring active upper limb therapy time during
weeks 1–14 (Table 1). Site personnel will explain the
booklets to them and phone them weekly to remind
them to complete their rehabilitation booklet.
Outcome assessments
Assessments will be performed at 6 and 14 weeks
(range 5–9 weeks and 13–17 weeks respectively) after
randomisation (Table 1) by trained site personnel.
These assessments will include measures with estab-
lished validity and reliability. As upper limb functional
recovery is a recognised research priority for stroke
survivors,12 the primary outcome is upper limb func-
tion measured by the ARAT at 6 weeks post random-
isation. The secondary outcomes are ARAT at 14
weeks post randomisation, and FMUE, VAS, MAL,
BI, mRS, SIS (full, plus hand domain only) and EQ-
5D-5L at 6 and 14 weeks. Resource use will be recorded
at 14 weeks also.
At 6 months a telephone follow-up will occur. This
will include the EQ-5D-5L, MAL, mRS and resource
utilisation. These are exploratory outcomes for eco-
nomic evaluation.
All outcome assessors will receive training on the
assessment before conducting any assessments.
Table 2. Inclusion and exclusion criteria.
Inclusion criteria
1. New clinical stroke diagnosis that occurred 7–60 days (inclusive) prior to randomisation
2. Age 18 years
3. ARAT 46 and FMUE hand sub-section 7 due to stroke
4. Capacity to consent to study participation with or without aphasia
5. Identified during stroke index admission with consent, baseline assessment and randomisation occurring as an inpatient or within
2weeks of discharge home
6. Considered eligible to use a SaeboGlove at consent/baseline assessment:
 Reduced active range of digital extension with wrist held passively in full extension at consent/baseline
 At least 5 passive wrist extension with fingers held passively in full extension
 Nil to minimal digital contractures (5–10 accommodated)
 Some initiation of gross active digital flexion (crude estimate 2 cm in thumb plus 1 other digit, using the tips of these digits as a
reference)
 Modified Ashworth Scale 2 in wrist/fingers and considered to have consistent hand opening / closing with SaeboGlove on to
enable grasp / release despite tone present
7. Considered able to don/doff a SaeboGlove and engage in independent rehabilitation with or without the help of a willing carer
8. Considered able to comply with the requirements of the protocol, including questionnaires with or without help from proxy
Exclusion criteria
1. Swelling of the paretic hand considered severe enough to cause discomfort when glove is worn
2. Other significant upper limb impairment e.g. fixed contracture, fracture within last 6months, frozen shoulder, severe arthritis,
amputation
3. Diagnosis likely to interfere with rehabilitation or outcome assessments e.g. registered blind or terminal illness
4. Participant in another intervention trial
ARAT: Action Research Arm Test; FMUE: Fugl Meyer Upper Extremity scale.
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This will include face to face training, provision of an
accompanying training manual and independent co-
scoring of each outcome measure a minimum of 3
times with a researcher with over 5 years’ scoring
experience.
Blinding and masking of treatment allocation
Outcome assessments will be conducted by a blinded
assessor. They will be asked to record if they have been
unblinded at each outcome visit to enable potential
bias to be reported. Given the interventions involved,
it is not possible to conceal group allocation from par-
ticipants or their therapist. Participants, therapists and
the clinical team will be asked not to let outcome asses-
sors know which treatment group participants are allo-
cated to.
At the baseline assessment all participants will be
given an identical small therapy box with a cardboard
insert weighing the same as a SaeboGlove, and a Hand
and Arm rehabilitation booklet specific for control par-
ticipants (Table 1). The box will have a note in it thank-
ing them for their participation in the SUSHI trial,
asking them to bring the box with their Hand and
Arm Therapy Booklets to their future study visits
and to not discuss the contents of the box or the treat-
ment group they are placed in with outcome assessors.
When participants in the intervention group are
given a SaeboGlove, it will be left in their therapy
box in exchange for the cardboard insert which their
therapist will remove. The Hand and Arm rehabilita-
tion booklet previously provided will also be swapped
for a booklet specific for the intervention group
(Table 1). All therapy booklets look identical from the
outside and would need to be opened and studied to
reveal group allocation. Regardless of group allocation,
therapy booklets, and all case report forms used for the
recording of usual care and upper limb therapy reviews
will appear identical externally and will not reveal group
allocation unless opened and studied. These measures
will help keep outcome assessors blinded.
After the week 14 visit, SaeboGlove therapy can be
offered to eligible controls, but outcome assessors
should remain blinded.
Statistical analysis
The Robertson Centre for Biostatistics within the
Glasgow Clinical Trials Unit will provide statistical
support to the trial. A statistical analysis plan will be
agreed and made available before completion of
enrolment.
Analysis will be performed on an intention to treat
basis. All efficacy measures will be compared between
randomised groups using linear regression (or other
appropriate regression method), adjusting for the base-
line value of the outcome, and minimisation variables.
If statistical models fail to converge, then a reduced
level of adjustment may be applied. Data may be trans-
formed prior to analysis to satisfy statistical modelling
assumptions. If no suitable regression model can be
identified, then groups will be compared using a strat-
ified Wilcoxon test (van Elteren test).27
Missing data
Missing data will not be imputed for the main statisti-
cal analyses. The sensitivity of analysis results may be
assessed under alternative assumptions regarding miss-
ing data, and/or through the use of multiple imputation
techniques.
Sample size calculation
A mean change in ARAT score of 10 points is assumed
in the control group.23 A mean difference between
groups of 9 points is being used for our sample size
calculation based on our pilot data where participants
improved by 19 points (standard deviation 13.5
points).19 A sample size of 49 per group will detect
this difference with 90% power at a 5% significance
level. Allowing for 11% attrition, we will randomise
up to 110 participants to achieve this number with a
6-week outcome measure.
Safety monitoring and analysis
Predicted adverse device effects will include discomfort
in the upper limb considered to be device related.
The safety of SaeboGlove self-directed, repetitive,
functional-based practice and usual care will be evalu-
ated by examining the occurrence of all adverse device
events (ADEs), serious adverse events (SAEs), serious
adverse device events (SADEs) and unexpected serious
adverse device events (USADEs) until the 14 week
visit.28 The occurrence of all such events will be
checked at all study visits. Additionally, participants
will be encouraged to report them between visits.
Participants undergoing SaeboGlove therapy who
have upper limb discomfort of a degree sufficient to
compromise function will have study therapy stopped.
Such participants will be allowed to resume therapy
should they wish and if their upper limb discomfort
improves, provided this is within the planned 6-week
intervention period.
Economic analysis
A within-trial cost-effectiveness analysis will be per-
formed from the perspective of NHS and Social
Services resource use. Costs will be calculated using
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routine data sources and data from a resource use ques-
tionnaire administered at baseline, 14 weeks and 6
months (further detail available in Supplement).
Health outcomes will be expressed as quality adjusted
life years using population tariffs and responses to the
EQ-5D-5L at baseline, 6 and 14 weeks and 6 months
(Table 1).
Process evaluation
To aid implementation an embedded process evalua-
tion will be performed involving the two currently
approved NHS Health Boards. Semi-structured inter-
views will be performed with a purposive sample of at
least six participants in the intervention group, four
carers and four therapists (two physiotherapists and
two occupational therapists) from each Board (further
detail available in Supplement).
Data management and clinical monitoring
All personal information will be collected, stored and
processed in accordance with the General Data
Protection Regulation (2018). Each person will be iden-
tified on case report forms only by their study number.
Site personnel will record data on paper source forms
and enter data into an electronic database.
A trial steering committee and a patient and carer
research advisory group has been convened and will
meet annually. Further details on these groups can be
found in the Supplement. A Data Monitoring
Committee has not been convened.
This study will be audited by designated representa-
tives of the Sponsor, NHS GG&C, according to their
audit processes.
Dissemination
The results of this trial will be presented at research
conferences and be published in peer-reviewed jour-
nals. A lay summary will be given to those participants
who wish to receive it (participants will be asked at
their last study visit). Anonymised data will be stored
on a research repository called Enlighten for 10 years
from the time of last data access and will be shared with
other organisations or universities to carry out research
to improve scientific understanding.
Discussion
Impaired active digital extension is the most common
motor impairment after stroke. It reduces hand open-
ing, hindering participation in self-directed and repeti-
tive functional-based rehabilitation recommended in
national clinical guidelines, predicts poor upper limb
recovery and may contribute significantly to the poor
upper limb prognosis experienced after stroke.
Evidence-based interventions for this group have yet
to be identified. The SaeboGlove is a rehabilitation
aid that assists hand opening, enabling greater access
to self-directed, repetitive, functional-based practice
and has been found to be a safe, feasible and acceptable
intervention early after stroke. A high-quality definitive
trial is now needed to assess the effectiveness and role
of the SaeboGlove in the treatment of the stroke affect-
ed hand and arm in the NHS. SUSHI is a multicentre
RCT to determine whether self-directed, repetitive,
functional-based practice involving a SaeboGlove
improves upper limb function early after stroke when
compared to usual NHS care. The results from the trial
will provide evidence on the clinical and cost effective-
ness of SaeboGlove self-directed, repetitive, functional-
based practice.
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